Statistical methods of HIV dynamic studies in AIDS clinical trials

Statistical Methods in Medical Research

Volumn 14, Issue 2, 2005, Pages 171-192

  Wu, Hulin ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BAYES THEOREM; DATA ANALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL MODEL; METHODOLOGY; REGRESSION ANALYSIS; REVIEW; STATISTICAL ANALYSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; BIOMETRY; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; LEAST-SQUARES ANALYSIS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; RNA, VIRAL;

EID: 16344394559     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280205sm390oa     Document Type: Review

References (91)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasmas virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-26.
2. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271: 582-86.
4. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-Infected compartments during combinations therapy. Nature 1997; 387: 188-91.
5. Wu H, Kuritzkes DR, McClernon DR, Kessler H, Connick E, Landay A, Spear G, Heath-Chiozzi M, Rousseau F, Fox L, Spritzler J, Leonard NM, Lederman MM. Characterization of viral dynamics in human immunodeficiency virus Type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration and virological endpoints. Journals of Infectious Diseases 1999; 179: 799-807.
6. Luzuriaga K, Wu H, McManus M, Britto P, Borkowsky W, Burchett S, Smith B, Mofenson L, Sullivan JL. Dynamics of HIV-1 replication in vertically-infected infants. Journal of Virology 1999; 73: 362-67.
7. Essunger P, Markowitz M, Ho DD, Perelson AS. Efficacy of drug combination and dosing regimen in antiviral therapy. The First International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida, USA, June 1997; Abstract 73: 48.
8. Ding AA and Wu H. Assessing antiviral potency of anti-HIV therapies in vivo by comparing viral decay rates in viral dynamic models. Biostatistics 2001; 2: 13-29.
9. Ding AA and Wu H. Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics. Mathematical Biosciences 1999; 160: 63-82.
10. Anderson RM, Darby SC. The role of statistics in human immunodeficiency virus research. Journal of Royal Statistical Society: Series A 1998; 161: 161-66.
11. Donnelly CA. The impact of the AIDS epidemic on medical statistics. Statistical Methods in Medical Research 2001; 10: 83-4.
12. Donnelly CA, Cox DR. Mathematical biology and medical statistics: contributions to the understanding of AIDS epidemiology. Statistical Methods in Medical Research 2001; 10: 141-54.
13. Raab GM, Parpia T. Random effects models for HIV marker data: practical approaches with currently available software. Statistical Methods in Medical Research 2001; 10: 101-16.
14. Cooper LN. Theory of an immune system retrovirus. Proceeding of the National Academy of Sciences of the United States of America 1986; 83: 9159-63.
15. Reibnegger G, Fuchs D, Hausen A, Werner, ER, Dierich MP, Wachter H. Theoretical implications of cellular immune reactions against helper lymphocytes infected by an immune system retrovirus. Proceedings of the National Academy of Sciences of the United States of America 1987; 84: 7270-74.
16. Dolezal J, Hraba T. Application of mathematical model of immunological tolerance to HIV infection. Folia Biol, 1988; 34 336-41.
17. Intrator N, Deocampo GP, Cooper LN. Analysis of immune system retrovirus equations. In AS Perelson ed. Theoretical Immunology, Part 2, Redwood City, CA: Addison-Wesley, 1988.
18. McLean AR. HIV infection from an ecological viewpoint. In Perelson AS ed. Theoretical Immunology Part 2. Redwood City, CA: Addison-Wesley, 1988.
19. Merrill S. AIDS: background and the dynamics of the decline of immunocompetence. In Perelson AS ed. Theoretical Immunology, Part 2. Redwood City, CA: Addison-Wesley, 1988.
20. Hraba T, Dolesal J. Mathematical model of CD4+ lymphocyte depletion in HIV infection. Folia Biol, 1989; 35: 156-63.
21. Merrill S. Modeling the interaction of HIV with the cells of the immune system. In Castillo-Chavez C ed. Mathematical and Statistical Approaches to AIDS Epidemiology, Volume 83. Lecture Notes in Biomathematics, New York: Springer-Verlag, 1989.
22. Perelson AS. Modeling the interaction of the immune system with HIV. In Castillo-Chavez, C. ed. Mathematical and Statistical Approaches to AIDS Epidemiology, Volume 83. Lecture Notes in Biomathematics, New York: Springer-Verlag, 1989.
23. Perelson AS, Kirschner DE, Boer RD. Dynamics of HIV infection of CD4+ T cells. Mathematical Biosciences 1993; 114: 81-125.
24. Kirschner DE, Perelson AS. A model for the immune system response to HIV: AZT treatment studies. In Arino O, Axelrod D, Kimmel M, Langlais M, eds. Mathematical population dynamics: analysis of heterogeneity, Volume 1. Theory of epidemics, 1995: 295-310.
25. McLean AR, Kirkwood TLB. A model of human immunodeficiency virus (HIV) infection in T-helper cell clones. Journal of Theoretical Biology 1990; 147: 177-203.
26. McLean AR, Nowak MA. Models of interactions between HIV and other pathogens. Journal of Theoretical Biology 1992; 155: 69-86.
27. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May RM. Antigenic diversity threshold and the development of AIDS. Science 1991; 254: 963-69.
28. Nowak MA, May RM. Mathematical Biology of HIV infections: antigenic variation and diversity threshold. Mathematical Biology 1991; 106: 1-21.
29. Schenzle D. A model for AIDS pathogenesis. Statistics in Medicine 1994; 13: 2067-79.
30. Stilianakis NI, Schenzle D, Dietz K. On the antigenic diversity threshold model for AIDS. Mathematical Biology 1994; 121: 235-47.
31. Huang Y, Rosenkranz S, Wu H. Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Mathematical Biosciences 2003; 184 165-86.
32. Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proceeding of the National Academy of Sciences of the United States of the America 1996; 93: 7247-51.
33. Wu H, Ding A. Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials. Biometric 1999; 55: 410-18.
34. Wu H, Ding AA, DeGruttola V. Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations? AIDS 1999; 13: 429-30.
35. Wu H, Zhang JT. The study of long-term HIV dynamics using semiparametric nonlinear mixed-effects models. Statistics in Medicine 2002; 21: 3655-75.
36. Perelson AS, Nelson PW. Mathematical Analysis of HIV-1 dynamics in vivo. SIAM Review 1999; 41: 3-44.
37. Nowak MA, May RM, Virus dynamics: mathematical principles of immunology and virology, Oxford University Press, 2000.
38. Callaway DS, Perelson AS. HIV-1 infection and low steady state viral loads. Bulletin of Mathematical Biology 2002; 64: 29-64.
39. Ratkowsky DA. Nonlinear regression modeling. New York: Marcel Dekker, 1983.
40. Bates DM, Watts DG. Nonlinear regression analysis and its applications. New York: John Wiley & Sons, 1988.
41. Seber GAF, Wild CJ. Nonlinear regression. New York: John Wiley & Sons, 1989.
42. Wu H, Ding A, DeGruttola V. Estimation of HIV dynamic parameters. Statistics in Medicine 1998; 17: 2463-85.
43. Davidian M, Giltinan DM. Nonlinear models for repeated measurements data. New York: Chapman & Hall, 1995.
44. Vonesh EF, Chinchilli VM. Linear and nonlinear models for the analysis of repeated Measurements, New York: Marcel Dakker, 1996.
45. Beal SL, Sheiner LB. Estimating population kinetics. CRC Critical Reviews in Biomedical Engineering 1982; 8: 195-222.
46. Vonesh EF, Carter RL. Mixed-effects nonlinear regression for unbalanced repeated measures. Biometrics 1992; 48: 1-18.
47. Lindstrom MJ, Bates DM. Nonlinear mixed-effects models for repeated measures. Biometrics 1990; 46: 673-87.
48. Pinheiro J, Bates D. Mixed-effects models in S and S-plus New York: Springer, 2000.
49. Beal SL, Sheiner LB. NONMEM user's guides. San Francisco: NONMEM Project Group, University of California, 1992.
50. Rice JA, Wu Co. Nonparametric mixed-effects models for unequally sampled noisy curves. Biometrics 2001; 57: 253-59.
51. Eubank RL. Spline smoothing and nonparametric regression New York: Marcel Dekker, 1988.
52. Eubank RL. Comment on 'Monotone regression splines in action' by JO Ramsay. Statistical Science 1988; 3: 425-61.
53. Frost SDW. Bayesian modeling of viral dynamics and evolution. AIDS Cyber Journal 2001, 4(2). [http://www.prous.com/ttm/spain/aids/aids (last accessed December 2002)].
54. Han C, Chaloner K, Perelson AS. Bayesian analysis of a population HIV dynamic model. In Case studies in Bayesian statistics, Volume 6. New York: Springer-Verlag, 2002.
55. Putter H, Heisterkamp SH, Lange JMA, Wolf F. A Bayesian approach to parameter estimation in HIV dynamic models. Statistics in Medicine 2002; 21: 2199-214.
56. Geman S, Geman D. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images. IEEE Transactions on Pattern Recognition and Machine Intelligence 1984; 6: 721-41.
57. Hastings WK, Monte Carlo sampling methods using Markov chains and their applications. Biometrika 1970; 57: 97-109.
58. Metropolis N, Rosenbluth AW, Rosenbluth MN, Teller AH, Teller E. Equations of state calculations by fast computing machine. Journal of Chemistry in Physics 1953; 21: 1087-91.
59. Smith AFM, Roberts GO. Bayesian computation via the Gibbs sampler and related Markov chain Monte Carlo methods. Journal of the Royal Statistical Society, Series B 1993; 55: 3-23.
60. Nowak MA, Bonhoeffer S, Clive L, Balfe P, Semple M, Kaye S, Tenant-Flowers M, Tedder R. HIV results in the frame. Nature 1995; 375: 193.
61. Huang Y, Wu H. Mechanistic PK/PD modeling of antiretroviral therapies in AIDS clinical trials. In David Z. D'Argenio ed. Advanced methods of pharmacokinetic pharmacodynamic & systems analysis, Volume 3. New York: Kluwer Academical Publishers, 2004; 221-37.
62. Brooks SP, Morgan BJT. Automatic starting pint selection for function optimization. Statistical Computation 1994; 4: 173-77.
63. Brooks SP, Morgan BJT. Optimization using simulated annealing. The Statistician 1995; 44: 241-57.
64. Wood SN. Minimizing model fitting objectives that contain spurious local minima by bootstrap restarting. Biometrics 2001; 57: 240-44.
65. Small CG, Wang J, Yang Z. Eliminating multiple root problems in estimation. Statistical Science 2000; 15: 313-41.
66. Ding AA, Wu H. A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies. Biometrics 2000; 56: 16-23.
67. Wu H, Ruan P, Ding AA, Sullivan JL, Luzuriaga K. Inappropriate model-fitting methods may lead to significant underestimates of viral decay rates in HIV dynamic studies. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1999; 21: 426-28.
68. Wu H, Zhao C, Liang H. Comparison of linear, nonlinear and semiparametric models for estimating HIV dynamic parameters. Biometrical Journal 2004, 46: 233-45.
69. Diggle PJ, Liang KY, and Zeger SL. Analysis of longitudinal data. New York: Oxford University Press, 1994.
70. Maitre PO, Buhrer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. Journal of Pharmacokinetics and Biopharmaceutics 1991; 19: 377-85.
71. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. Journal of Pharmacokinetics and Biopharmaceutics 1992; 20: 511-29.
72. Wu H, Wu L. Identification of significant host factors for HIV dynamics modeled by nonlinear mixed-effect models. Statistics in Medicine 2002; 21: 753-71.
73. Wu H, Wu L. A multiple imputation method for missing covariates in nonlinear mixed-effect models, with application to HIV dynamics. Statistics in Medicine 2001; 20: 1755-69.
74. Wu L, Wu H. Nonlinear mixed-effect models with missing time-dependent covariates, with application to HIV viral dynamics. Journal of the Royal Statistical Society, Series C (Applied Statistics) 2002; 51: 297-318.
75. Rubin DB. Inference and missing data. Biometrika 1976; 63: 581-92.
76. Weinberg JM, Lagakos SW. Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data. Statistics in Medicine 2000; 20: 705-31.
77. McCullagh P, Nelder JA. Generalized linear models. New York: Chapman and Hall, 1989.
78. Marschner IC. Design of HIV viral of dynamics studies. Statistics in Medicine 1998; 17: 2421-34.
79. Wu H, Ding AA. Design of viral dynamic studies for efficiently assessing anti-HIV therapies in AIDS clinical trials. Biometrical Journal 2000; 2: 175-96.
80. Wu H. How frequently should viral load be monitored to evaluate antiretroviral therapies in AIDS clinical trials? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1999; 20: 97-99.
81. Johnson SCD. The role of simulation in the management of research: what can the pharmaceutical industry learn from the aerospace industry. Drug Information Journal 1998; 32: 961-69.
82. Bonate PL. Clinical trial simulation in drug development. Pharmaceutical Research 2000; 17: 252-56.
83. Holford NHG, Hale, M, Ko HC, Steimer J-L, Sheiner LB, Peck CC. Simulation in drug development: good practices. Download from webpage: http://www.Cdds.georgetown.edu/research/sddgp723.html [accessed 30/4/04] 1999.
84. Holford NHG, Kimko HC, Monteleone JPR, Peck CC. Simulation of clinical trials. Annual Review of Pharmacology and Toxicology 2000; 40: 209-34.
85. Krall RL, Engleman KH, Ko HC, Peck CC. Clinical trial modeling and simulation - work in progress. Drug Information Journal 1998; 32: 971-76.
86. Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulation: a case study. Statistics in Medicine 2001; 20: 75-91.
87. Wu H, Lathey J, Ruan P, Douglas SD, Spector SA, Lindsey J, Hughes MD, Rudy BJ, Flynn PM. Relationship of plasma HIV-1 RNA dynamics to baseline factors and virological responses to highly active antiretroviral therapy (HAART) in adolescents (aged 12-22 Years) infected through risk behavior. Journal of Infectious Diseases 2004; 189 593-601.
88. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, Mcdade H. Viral dynamics in hepatitis B virus infection. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 4398-402.
89. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 103-107.
90. Wu H, Tan WY. Modeling HIV epidemic: a state-space approach. Mathematical and Computer Modelling 2000; 32: 197-215.
91. Tan WY. Stochastic modeling of AIDS epidemiology and HIV pathogenesis. London: World Scientific, 2000.